Codon-Optimized GALC Genes for Therapeutic Neural Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Krabbe disease, such as hematopoietic stem cell therapy, are limited in effectiveness and have significant complications, and there is a need for a treatment that targets the underlying cause of the disease, namely GALC gene mutations.
Innovation Solution
Development of codon-optimized GALC genes, expression cassettes, and vectors that provide therapeutic levels of GALC expression to treat disorders associated with aberrant GALC gene activity, including Krabbe disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hematopoietic stem cell therapy is used to treat Krabbe disease, then some functional improvements are achieved, but the treatment has substantial limitations including 20% mortality risk, graft-versus-host disease in 10% of patients, and requires myeloablative procedures
Solution Approach 1:
The patent extracts and addresses the specific harmful elements (mortality risk, graft-versus-host disease, myeloablative procedures) from the conventional hematopoietic stem cell therapy by developing an alternative gene therapy approach using AAV vectors that delivers functional GALC gene directly to neural tissues, bypassing the need for stem cell transplantation and myeloablative conditioning
Solution Approach 2:
The patent introduces adeno-associated virus (AAV) vectors as an intermediary delivery system to transport the functional GALC gene directly to neural tissues, replacing the need for hematopoietic stem cells as the therapeutic intermediary. This direct gene delivery approach avoids the complications of stem cell engraftment while achieving therapeutic GALC expression in the nervous system
2Reliability
If conventional GALC gene sequences are used for gene therapy, then the gene can be delivered to cells, but expression levels are insufficient to achieve therapeutic effect
Solution Approach 1:
The patent applies codon optimization to the GALC gene sequence, systematically changing nucleotide parameters while maintaining the same amino acid sequence. This optimization of codon usage frequencies and nucleotide composition parameters dramatically enhances transcriptional and translational efficiency, achieving therapeutic expression levels of GALC enzyme in neural tissues that were not attainable with conventional gene sequences
Data Source
AI summary
This invention relates to polynucleotides comprising optimized GALC open reading frame (ORF) sequences, vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of a GALC gene or aberrant activity of a GALC gene product in the subject, such as Krabbe disease (i.e., globoid cell leukodystrophy (GLD)).